Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT06719817
Recruiting Observational

Evaluation of Some Trace Elements in Follicular Fluid in ICSI Cases and Their Effect on ICSI Outcomes

NCT06719817 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2024-11-24
Last updated
2024-12-06

Condition(s) studied

Good Responders According to Guidelines Who Wre Charectarized by AMH>0.8ng/dlTrace Elements in ICSI Cases

Study summary

To evaluate concentrations of some trace elements in the follicular fluid and their reproductive outcomes.

Eligibility

Sex
FEMALE
Min age
25 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria:good responders according to NICE guidelines with AMH more than 0.8ng/dl and antral follicular count more than 4 Exclusion Criteria:Poor responders according to ESHRE guidelines as advanced maternal age poor ovarian response and according to NICE guidelines AMH less than 0.8ng/dl

Primary outcome measure(s)

  • oocyte maturity — 2024 to 2026
    Millimetres

Trial sites (2)

FacilityCityRegionStatus
Faculty of medicine Asyut Egypt Recruiting
Faculty of medicine Asyut Egypt Recruiting

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06719817 on ClinicalTrials.gov ↗ ← All trials in Egypt